197 related articles for article (PubMed ID: 17210715)
1. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
Eichenauer DA; Simhadri VL; von Strandmann EP; Ludwig A; Matthews V; Reiners KS; von Tresckow B; Saftig P; Rose-John S; Engert A; Hansen HP
Cancer Res; 2007 Jan; 67(1):332-8. PubMed ID: 17210715
[TBL] [Abstract][Full Text] [Related]
2. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2.
Velásquez SY; García LF; Opelz G; Alvarez CM; Süsal C
Transplantation; 2013 Jul; 96(2):154-61. PubMed ID: 23857000
[TBL] [Abstract][Full Text] [Related]
3. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
4. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-beta precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases.
Jacobsen KT; Adlerz L; Multhaup G; Iverfeldt K
J Biol Chem; 2010 Apr; 285(14):10223-31. PubMed ID: 20139073
[TBL] [Abstract][Full Text] [Related]
6. Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.
Nagata S; Ise T; Onda M; Nakamura K; Ho M; Raubitschek A; Pastan IH
Proc Natl Acad Sci U S A; 2005 May; 102(22):7946-51. PubMed ID: 15905329
[TBL] [Abstract][Full Text] [Related]
7. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5.
Hansen HP; Recke A; Reineke U; Von Tresckow B; Borchmann P; Von Strandmann EP; Lange H; Lemke H; Engert A
FASEB J; 2004 May; 18(7):893-5. PubMed ID: 15033921
[TBL] [Abstract][Full Text] [Related]
8. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
9. ADAM10 mediates the house dust mite-induced release of chemokine ligand CCL20 by airway epithelium.
Post S; Rozeveld D; Jonker MR; Bischoff R; van Oosterhout AJ; Heijink IH
Allergy; 2015 Dec; 70(12):1545-52. PubMed ID: 26296735
[TBL] [Abstract][Full Text] [Related]
10. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
11. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
12. Ectodomain shedding of TNF-alpha is enhanced by nardilysin via activation of ADAM proteases.
Hiraoka Y; Yoshida K; Ohno M; Matsuoka T; Kita T; Nishi E
Biochem Biophys Res Commun; 2008 May; 370(1):154-8. PubMed ID: 18355445
[TBL] [Abstract][Full Text] [Related]
13. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
14. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
Hansen HP; Trad A; Dams M; Zigrino P; Moss M; Tator M; Schön G; Grenzi PC; Bachurski D; Aquino B; Dürkop H; Reiners KS; von Bergwelt-Baildon M; Hallek M; Grötzinger J; Engert A; Paes Leme AF; Pogge von Strandmann E
Oncotarget; 2016 May; 7(21):30523-35. PubMed ID: 27105521
[TBL] [Abstract][Full Text] [Related]
15. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases.
Zhang L; Bukulin M; Kojro E; Roth A; Metz VV; Fahrenholz F; Nawroth PP; Bierhaus A; Postina R
J Biol Chem; 2008 Dec; 283(51):35507-16. PubMed ID: 18952609
[TBL] [Abstract][Full Text] [Related]
16. ADAM10: a new player in breast cancer progression?
Mullooly M; McGowan PM; Kennedy SA; Madden SF; Crown J; O' Donovan N; Duffy MJ
Br J Cancer; 2015 Sep; 113(6):945-51. PubMed ID: 26284334
[TBL] [Abstract][Full Text] [Related]
17. Ectodomain shedding of Fcalpha receptor is mediated by ADAM10 and ADAM17.
Peng M; Guo S; Yin N; Xue J; Shen L; Zhao Q; Zhang W
Immunology; 2010 May; 130(1):83-91. PubMed ID: 20059578
[TBL] [Abstract][Full Text] [Related]
18. Role of ADAM10 and ADAM17 in CD16b shedding mediated by different stimulators.
Guo S; Peng M; Zhao Q; Zhang W
Chin Med Sci J; 2012 Jun; 27(2):73-9. PubMed ID: 22770404
[TBL] [Abstract][Full Text] [Related]
19. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10.
Parkin E; Harris B
J Neurochem; 2009 Mar; 108(6):1464-79. PubMed ID: 19183255
[TBL] [Abstract][Full Text] [Related]
20. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Saftig P; Reiss K
Eur J Cell Biol; 2011; 90(6-7):527-35. PubMed ID: 21194787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
